Promising new combo therapy targets hard-to-treat lymphoma

This study tests a new treatment for people with a type of blood cancer called diffuse large B-cell lymphoma that has come back or not responded to prior therapy. The treatment combines two drugs (tafasitamab and lenalidomide) with standard chemotherapy, followed by a stem cell transplant using the patient's own cells. The goal is to see if this approach can shrink or eliminate the cancer in more patients.